VitaDAO, a collective backed by pharmaceutical giant Pfizer and an array of venture capital firms, is currently voting on a proposal to create a for-profit company to fund research into longevity. The purpose of this new company, called VitaTech, is to secure and distribute public funding to the development of life-extension technologies.

Funding for VitaTech will come from a range of sources, including foundations and government grants such as SBIR (Small Business Innovation Research) and STTR (Small Business Technology Transfer). If approved, the proposal will enter an execution phase of 10 weeks between April 3 and June 12, 2023. VitaTech will operate as a subsidiary or affiliate of VitaDAO and will provide start-ups with international resources and opportunities to bring their research to market.

This proposal by VitaDAO follows the $4.1M funding round involving Pfizer Ventures and several other investors that took place in January this year. This is believed to be the first time a pharmaceutical giant has made an investment into a decentralized autonomous organization, showing the potential for digital platforms to drive research and development.

VITA, the cryptocurrency associated with VitaDAO, has seen a positive return as a result of news regarding the collective and its investments, with prices increasing by 3% in the last 24 hours.

This is an exciting step forward in the world of longevity research and finance, and the potential implications involved in the development of both distributed organizations and life-extension technologies make this proposal one to keep an eye on.



Other News from Today